Cargando…

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion

Detalles Bibliográficos
Autores principales:	Bachert, Claus, Price, David, Scadding, Glenis, Fokkens, Wytske, Hellings, Peter, Munzel, Ullrich, Bousquet, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716593/ http://dx.doi.org/10.1186/2045-7022-3-S2-P39

Ejemplares similares

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

Deposition characteristics of a new allergic rhinitis nasal spray (MP29-02*) in an anatomical model of the human nasal cavity
por: D’Addio, Alex, et al.
Publicado: (2015)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Rhinitis and Sinusitis
por: Scadding, Glenis K.
Publicado: (2008)

Real-life effectiveness of a new allergic rhinitis therapy (MP29-02*) in Sweden
por: Stjärne, Pär, et al.
Publicado: (2015)

Optimal management of allergic rhinitis
por: Scadding, Glenis K
Publicado: (2015)

PD15 - MP29-02 effectively relieves both nasal and ocular symptoms in adolescents aged 12-17 years: results from a meta-analysis of 4 randomised controlled Seasonal Allergic Rhinitis (SAR) trials
por: Valovirta, Erkka, et al.
Publicado: (2014)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management
por: Bachert, C., et al.
Publicado: (2018)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment
por: Hoffmans, Ruth, et al.
Publicado: (2018)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

Thoughts on the pathophysiology of nonallergic rhinitis
por: Fokkens, Wytske J.
Publicado: (2002)

Upper Airway Disease: Rhinitis and Rhinosinusitis
por: Scadding, Glenis K., et al.
Publicado: (2012)

Rhinitis, sinusitis and ocular disease – 2091. The MSYPQ: repeatability and applicability to rhinitis/rhinosinusitis
por: Sami, Amtul Salam, et al.
Publicado: (2013)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

Diagnostic strategies in nasal congestion
por: Krouse, John, et al.
Publicado: (2010)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

Treatment of congestion in upper respiratory diseases
por: Meltzer, Eli O, et al.
Publicado: (2010)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

Quality of life and use of medication in chronic allergic and non-allergic rhinitis patients
por: Segboer, Christine, et al.
Publicado: (2013)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

Fractional exhaled nitric oxide (FeNO) measurement in asthma and rhinitis
por: Gevorgyan, Artur, et al.
Publicado: (2013)

New insights into the pathogenesis of non-allergic rhinitis
por: Segboer, Christine, et al.
Publicado: (2015)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome
por: Roufosse, Florence, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_famba7sq15rqjgfdfslfiddgra